A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia

European Neuropsychopharmacology

Volumn 17, Issue 6-7, 2007, Pages 456-463

  Arango, C ^a   Gomez Beneyto M ^b   Brenlla, J ^c   Gasto C ^d   Sarramea Crespo, F ^e   Chamorro, L ^f   Masramon, X ^g   Diez T ^h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c CSM Fontiñas   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e CSM Andújar   (Spain)

^f HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^g European Biometrics Institute   (Spain)

^h PFIZER INC   (United States)

Author keywords

Antipsychotics; Naturalistic studies; Schizophrenia; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RIGIDITY; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERAZINES; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SPAIN; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34047173462     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.11.007     Document Type: Article

References (51)

1. Addington D.E., Pantelis C., Dineen M., Bemattia I., Romano S.J., and Murray S.R. Ziprasidone vs risperidone in schizophrenia: 52 weeks' comparative data. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, California (2003)
2. Addington D.E., Pantelis C., Dineen M., Benattia I., and Romano S.J. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J. Clin. Psychiatry 65 (2004) 1624-1633
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Second ed. (2004), American Psychiatric Association
5. Arango C., Buchanan R.W., Kirkpatrick B., and Carpenter W.T. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur. Psychiatry 19 (2004) 21-26
6. Arato M., O'Connor R., Meltzer H.Y., and ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 17 (2002) 207-215
7. Artaloytia J.F., Arango C., Lahti A., Sanz J., Pascual A., Cubero P., Prieto D., and Palomo T. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am. J. Psychiatry 163 (2006) 488-493
8. Bagnall A.-M., Lewis R.A., Leitner M.L. (2004). Ziprasidone for schizophrenia and severe mental illness (Cochrane Review). The Cochrane Library, Issue 1, Oxford.
9. Carpenter Jr. W.T., Arango C., Buchanan R.W., and Kirkpatrick B. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol. Psychiatry 46 (1999) 352-360
10. Daniel D.G. Tolerability of ziprasidone: an expanding perspective. J. Clin. Psychiatry 64 Suppl. 19 (2003) 40-49
11. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., and Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20 (1999) 491-505
12. Dickey B. Outcome measurement from research to clinical practice. In: IsHak W.W., Burt T., and Sederer L.I. (Eds). Outcome measurement in psychiatry. A critical review (2002), American Psychiatric Publishing Inc, Washington, DC
13. Di{dotless}az-Mataix L., Scorza M., Bortolozzi M.C., Toth A., and Celada M. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25 47 (2005) 10831-10843
14. Emsley R.A., Raniwalla J., Bailey P.J., and Jones A.M. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol. 15 (2000) 121-131
15. Friedman L.M., Furberg C.D., and DeMets D.L. Fundamentals of Clinical Trials. Third ed. (1998), Springer-Verlag, New York
16. Garcia I., Hormaechea J.A., Arango C., Sanz M., and González de Chávez M. El Cuestionario de Actitud hacia la Medicación (Drug Attitude Inventory: DAI-30) en población española. Arch. Psiquiatr. 64 (2001) 261-272
17. Gasquet I., Haro J.M., Novick D., Edgell E.T., Kennedy L., Lepine J.P., and SOHO Study Group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int. Clin. Psychopharmacol. 20 (2005) 199-205
18. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., Wilner K.D., Law C.G., and Ko G.N. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol. 18 (1998) 296-304
19. Gomez J.C., Sacristan J.A., Hernandez J., Breier A., Ruiz Carrasco P., Anton Saiz C., and Fontova Carbonell E. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J. Clin. Psychiatry. 61 (2000) 335-343
20. Grimes D.A., and Schulz K.F. An overview of clinical research: the lay of the land. Lancet 359 (2002) 57-61
21. Guy W., 1976. ECDEU Assessment Manual for Psychopharmacology -Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp. 218-222.
22. Haro J.M., Edgell E.T., Novick D., Alonso J., Kennedy L., Jones P.B., Ratcliffe M., Breier A., and SOHO advisory board. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 111 (2005) 220-231
23. Hirsch S.R., Kissling W., Bauml J., Power A., and O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J. Clin. Psychiatry 63 (2002) 516-523
24. Hofer A., Hummer M., Huber R., Kurz M., Walch T., and Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol. 20 (2000) 699-702
25. Hogan T.P., Awad A.G., and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 13 (1983) 177-183
26. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical Dictionary for Regulatory Affaire, MedDRA V 8.0, 1 March 2005.
27. Kane J.M. Management Issues in Schizophrenia (2000), Martin Dunitz Ltd, London
28. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 64 Suppl. 12 (2003) 1-100
29. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
30. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23 (1988) 99-110
31. Kazis L.E., Anderson J.J., and Meenan R.F. Effect sizes for interpreting changes in health status. Med. Care 27 (1989) S178-S189
32. Keck Jr. P., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., and Morrissey M.R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140 (1998) 173-184
33. Larmo I., Nayer A., Windhager E., Irmansyah, Lindenbauer B., Rittmannsberger H., Platz T., Jones A.M., Altman C., and Spectrum Study Group. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Hum. Psychopharmacol. 20 (2005) 573-581
34. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 22 (2005) 1209-1223
35. In: McEvoy J.P., Scheifler P.L., and Frances A. (Eds). The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J. Clin. Psychiatry vol. 60 (1999) 1-80 Suppl. 11
36. Murray S., Siu C.O., and Romano S.J. Optimal dosing of oral ziprasidone: analysis of clinical trial data. Presented at the 156th Annual Meeting of the American Psychiatric Association; May 17-22, San Francisco, California (2003)
37. Norquist G., Lebowitz B., and Hyman S. Expanding the frontier of treatment research. Prev. Treat. 2 (1999) 0001a. http://content.apa.org/journals/pre/2/1/1 http://content.apa.org/journals/pre/2/1/1
38. Osser D.N., and Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv. Rev. Psychiatry 9 (2001) 89-104
39. Peralta V., and Cuesta M.J. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Esp. Neurol. Psiquiatr. 22 (1994) 171-177
40. Siegfried S.L., Fleischhacker W., and Lieberman J.A. Pharmacological treatment of schizophrenia. In: Lieberman J.A., and Murray R.M. (Eds). Comprehensive care of schizophrenia. A textbook of clinical management (2001), Martin Dunitz, London
41. Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., and Siu C.O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161 (2004) 1837-1847
42. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am. J. Psychiatry 162 (2005) 1535-1538
43. Stahl S.M. Does evidence from clinical trials in psychopharmacology apply in clinical practice?. J. Clin. Psychiatry 62 (2001) 6-7
44. Stahl S.M., and Shayegan D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry 64 Suppl. 19 (2003) 6-12
45. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J. Psychiatry Neurosci. 25 (2000) 137-153
46. Streiner D.L. The 2 "Es" of research: efficacy and effectiveness trials. Can. J. Psychiatry 47 (2002) 552-556
47. Stroup T.S., Alves W.M., Hamer R.M., and Lieberman J.A. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat. Rev., Drug Discov. 5 (2006) 133-146
48. Tamminga C.A., Buchanan R.W., and Gold J.M. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int. Clin. Psychopharmacol. 13 Suppl. 3 (1998) S21-S26
49. Thornley B., and Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 317 (1998) 1181-1184
50. Umbricht D.S., Wirshing W.C., Wirshing D.A., McMeniman M., Schooler N.R., Marder S.R., and Kane J.M. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J. Clin. Psychiatry 63 (2002) 420-424
51. Wells K.B. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am. J. Psychiatry 156 (1999) 5-10